217 search results for: burden of disease
Bullous Pemphigoid (BP): Don't Miss the Diagnosis
This static infographic covers the clinical presentations, diagnostic challenges, and disease burden of bullous pemphigoid (BP), a chronic relapsing autoimmune skin disease. Review the steps of diagnosis, which include clinical assessment and laboratory work. Explore comorbidities associated with BP and how they impact patient quality of life.
Assessment of Smell Loss in CRSwNP Interactive Infographic
Use this educational tool to explore the daily burden of loss of smell for patients with CRSwNP.
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
European Academy of Dermatology and Venereology (EADV) 2023 | Berlin
ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
ADVENT at CEORL-HNS 2026
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Pediatric EoE Disease Burden Infographic
Learn about pediatric EoE disease burden and why early identification is key for pediatric patients with EoE
ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis
Hear Dr. Wechsler and Prof. Bredenoord discuss the multifaceted burden of EoE and how to overcome challenges in identifying EoE in clinical practice.
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.
The Shared Path: Type 2 Inflammation As a Driver of Chronic Itch
Professor Matthias Augustin highlights the role of type 2 inflammation in chronic itch across distinct pruritic skin diseases and the cumulative burden of chronic itch and skin lesions in PN.
